How do we value a cure?

被引:13
作者
Husereau, Don [1 ]
机构
[1] Inst Hlth Econ, Ottawa, ON, Canada
关键词
consumer behavior; economics; diffusion of innovation; financial; health; insurance; patient preference; reimbursement; reimbursement mechanisms; risk sharing; HEALTH-CARE; INNOVATIVE TECHNOLOGIES; DECISION-ANALYSIS; TASK-FORCE; PREFERENCES; PREVENTION; DESIGN; RISK;
D O I
10.1586/14737167.2015.1039519
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Future perceptions of the value of curative therapies will likely reflect debates happening today about preferences for funding of preventive versus treatment programs, as well as funding orphan drugs. Little is known about how society will value curative therapies versus standard treatments, and the significant role of a host of psychological factors compared to overarching concerns about opportunity costs will likely lead to significant tension between payers and the public. More research to clarify societal preferences and healthcare goals in regards to curative therapies and in light of the potential for significant opportunity costs will be required. Given what we know about preferences for the funding of prevention and treatment measures, we should expect that cures will not be held to a different measure.
引用
收藏
页码:551 / 555
页数:5
相关论文
共 27 条
[1]  
[Anonymous], 1911, BR MED J, V1, P945
[2]   Is an Ounce of Prevention Worth a Pound of Cure? Comparing Demand for Public Prevention and Treatment Policies [J].
Bosworth, Ryan ;
Cameron, Trudy Ann ;
DeShazo, J. R. .
MEDICAL DECISION MAKING, 2010, 30 (04) :E40-E56
[3]   TRYING TO VALUE A LIFE [J].
BROOME, J .
JOURNAL OF PUBLIC ECONOMICS, 1978, 9 (01) :91-100
[4]  
Claxton K, 2012, METHODS ESTIMATION N
[5]   Eliciting Preferences for Prioritizing Treatment of Rare Diseases: the Role of Opportunity Costs and Framing Effects [J].
Desser, Arna S. ;
Olsen, Jan Abel ;
Grepperud, Sverre .
PHARMACOECONOMICS, 2013, 31 (11) :1051-1061
[6]   How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide [J].
Diaby, Vakaramoko ;
Goeree, Ron .
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (01) :81-99
[7]   Challenges in Measuring the Societal Value of Orphan Drugs: Insights from a Canadian Stated Preference Survey [J].
Dragojlovic, Nick ;
Rizzardo, Shirin ;
Bansback, Nick ;
Mitton, Craig ;
Marra, Carlo A. ;
Lynd, Larry D. .
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2015, 8 (01) :93-101
[8]   Orphan drugs policies: a suitable case for treatment [J].
Drummond, Michael ;
Towse, Adrian .
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 (04) :335-340
[9]   Sharing Risk between Payer and Provider by Leasing Health Technologies: An Affordable and Effective Reimbursement Strategy for Innovative Technologies? [J].
Edlin, Richard ;
Hall, Peter ;
Wallner, Klemens ;
McCabe, Christopher .
VALUE IN HEALTH, 2014, 17 (04) :438-444
[10]  
Ellsberg D, 2001, RISK AMBIGUITY DECIS, P288